FDA Considers Restricting Future COVID-19 Vaccines to At-Risk Groups and Older Adults

The US Food and Drug Administration is revising its approval process for Covid-19 vaccines, potentially restricting future doses to older individuals and those at high risk for severe infection. This new approach, revealed by Dr. Vinay Prasad and FDA Commissioner Dr. Marty Makary in a New England Journal of Medicine editorial, will change the evidence required from manufacturers for updated vaccines. Expected this fall, these shots may primarily benefit adults aged 65 and over, as well as those with underlying health issues, leaving healthy adults and children potentially without access. This policy aligns the US more closely with UK, Canadian, and Australian guidelines, yet raises concerns regarding equitable access and long-term health implications, particularly for younger populations. Critics emphasize the importance of broader vaccination in combating Covid-19 effectively.